category,datetime,headline,id,image,related,source,summary,url
company,1768255642,44th Annual J.P. Morgan Healthcare Conference,138079971,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"2026-01-12. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",https://finnhub.io/api/news?id=fbaa435359f11c009eb322df667a021f8d09bfbf6fb7aec34687d44ecb96476f
company,1768248967,"Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",138079530,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (REGN) 44th Annual J.P.",https://finnhub.io/api/news?id=8de76eaf6ec80f09c57050d4311cc2de0d017e442d8cedb29ffcaf69d40aefa8
company,1768247820,Adimab Reports Strong Partnering Year for 2025,138078029,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.",https://finnhub.io/api/news?id=0ea5b719e7392abac7aa1fdfe58b8bfdc207fca01ab520e4e7c8d919405bb0a0
company,1768236060,Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors,138129705,,REGN,MarketWatch,Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors,https://finnhub.io/api/news?id=73f16550ec18e30a99841e11db8604a4e6e7e19f75dc0e9d9b9b8c002cac6353
company,1768223911,"Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba",138085783,https://image.cnbcfm.com/api/v1/image/108251313-17682410851768241080-43461834838-1080pnbcnews.jpg?v=1768241084&w=1920&h=1080,REGN,CNBC,The Investment Committee give you their top stocks to watch for the second half.,https://finnhub.io/api/news?id=33d41bfe86ebfc5bee70b47684d840089d1493020862526cf2fc20167dc82bf8
company,1768184164,FPX: Leading IPO ETF With A Few Unexpected Holdings,138068572,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2207303700/image_2207303700.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"FPX holds 101 IPO and spin-off stocks in 1,000 days, across tech, industrials, healthcare, strong returns, 14% seasoned via M&A. Read why FPX ETF is a hold.",https://finnhub.io/api/news?id=b27e0a6b1a91325bca2c086dae18f6ba229f776a91d9f17191e0d0ec2c397e58
company,1768181492,A big Wall Street flip just changed the Regeneron narrative,138069196,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"Bank of America Global Research upped its rating on Regeneron Pharmaceuticals and its price target to $860 because it has a better view on Eylea HD, Dupixent is growing steadily, and there are several catalysts for 2026. Bank of America Global Research raised its rating on Regeneron ...",https://finnhub.io/api/news?id=beab187b4ccfad430be22b4edc548a86958427463f04b4e58e3da37e069f792b
